Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 8, 2015, Pages 458-463

  Rohlfing, Sarah ^a   Aurich, Matthias ^a   Schöning, Tilman ^a   Ho, Anthony D ^a   Witzens Harig, Mathias ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cardiac toxicity; DLBCL; Elderly; Liposomal doxorubicin; Reduced LVEF

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMORBIDITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; MALE; MIDDLE AGED; MORTALITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; RIGOR; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DISEASE FREE SURVIVAL; HEART DISEASES; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84937817726     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.03.008     Document Type: Article

References (38)

1. S. Luminari, A. Montanini, and M. Federico Anthracyclines: a cornerstone in the management of non-Hodgkin lymphoma Hematol Rep 3 2011 e4
2. B. Coiffier, E. Lepage, J. Briere, and et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 2002 235 242
3. D.L. Hershman, R.B. McBride, A. Eisenberger, W.Y. Tsai, V.R. Grann, and J.S. Jacobson Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin lymphoma J Clin Oncol 26 2008 3159 3165
4. D.D. Von Hoff, M.W. Layard, P. Basa, and et al. Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
5. S.M. Swain, F.S. Whaley, and M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879
6. O. Hequet, Q.H. Le, I. Moullet, and et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults J Clin Oncol 22 2004 1864 1871
7. A.M. Rahman, S.W. Yusuf, and M.S. Ewer Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation Int J Nanomedicine 2 2007 567 583
8. L.A. Smith, V.R. Cornelius, C.J. Plummer, and et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer 10 2010 337
9. D. Bovelli, G. Plataniotis, and F. Roila Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines Ann Oncol 21 suppl 5 2010 v277 v282
10. B.M. Aleman, A.W. van den Belt-Dusebout, M.L. De Bruin, and et al. Late cardiotoxicity after treatment for Hodgkin lymphoma Blood 109 2007 1878 1886
11. P. Feugier, A. Van Hoof, C. Sebban, and et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 2005 4117 4126
12. S.M. Swain, F.S. Whaley, M.C. Gerber, M.S. Ewer, J.R. Bianchine, and R.A. Gams Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy J Clin Oncol 15 1997 1333 1340
13. M. Bjorkholm, T. Andersson, A. Ahlbom, and E. Osby CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis) Eur J Haematol 80 2008 477 482
14. M.L. Hensley, K.L. Hagerty, T. Kewalramani, and et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants J Clin Oncol 27 2009 127 145
15. P.G. Tardi, N.L. Boman, and P.R. Cullis Liposomal doxorubicin J Drug Target 4 1996 129 140
16. G. Batist, G. Ramakrishnan, C.S. Rao, and et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 2001 1444 1454
17. K.A. Wouters, L.C. Kremer, T.L. Miller, E.H. Herman, and S.E. Lipshultz Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies Br J Haematol 131 2005 561 578
18. M.S. Ewer, F.J. Martin, C. Henderson, C.L. Shapiro, R.S. Benjamin, and A.A. Gabizon Cardiac safety of liposomal anthracyclines Semin Oncol 31 suppl 13 2004 161 181
19. C.E. Swenson, L.E. Bolcsak, G. Batist, and et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer Anticancer Drugs 14 2003 239 246
20. T.M. Allen, and F.J. Martin Advantages of liposomal delivery systems for anthracyclines Semin Oncol 31 suppl 13 2004 5 15
21. C.J. Schmitt, S. Dietrich, A.D. Ho, and M. Witzens-Harig Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin lymphoma patients with cardiac risk factors Ann Hematol 91 2012 391 397
22. A. Tulpule, B.M. Espina, N. Berman, and et al. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma Clin Lymphoma Myeloma 7 2006 59 64
23. B.D. Cheson, S.J. Horning, B. Coiffier, and et al. Report of an international workshop to standardize response criteria for non-Hodgkin lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
24. R.M. Lang, M. Bierig, R.B. Devereux, and et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
25. M. Pfreundschuh, J. Schubert, M. Ziepert, and et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 2008 105 116
26. D. Cunningham, E.A. Hawkes, A. Jack, and et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Lancet 381 2013 1817 1826
27. R. Delarue, H. Tilly, N. Mounier, and et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial Lancet Oncol 14 2013 525 533
28. L. Rigacci, S. Mappa, L. Nassi, and et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines Hematol Oncol 25 2007 198 203
29. S. Luminari, A. Montanini, D. Caballero, and et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial Ann Oncol 21 2010 1492 1499
30. D. Heintel, C. Skrabs, A. Hauswirth, and et al. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age Ann Hematol 89 2010 163 169
31. E. Gimeno, B. Sanchez-Gonzalez, A. Alvarez-Larran, and et al. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma Leuk Res 35 2011 358 362
32. G. Corazzelli, F. Frigeri, M. Arcamone, and et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy Br J Haematol 154 2011 579 589
33. G. Visani, F. Ferrara, F. Alesiani, and et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study Leuk Lymphoma 49 2008 1081 1086
34. R. Altena, P.J. Perik, D.J. van Veldhuisen, E.G. de Vries, and J.A. Gietema Cardiovascular toxicity caused by cancer treatment: strategies for early detection Lancet Oncol 10 2009 391 399
35. A. Schlitt, K. Jordan, D. Vordermark, J.R. Schwamborn, T. Langer, and C. Thomssen Cardiotoxicity and oncological treatments Dtsch Arztebl Int 111 2014 161 168
36. M. Dessi, A. Piras, C. Madeddu, and et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction Exp Ther Med 2 2011 1003 1009
37. X. Bosch, M. Rovira, M. Sitges, and et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 2013 2355 2362
38. A.A. Moccia, K. Schaff, P. Hoskins, and et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines ASH Annual Meeting Abstracts 114 2009 abstract 408